RxDoctor Payments DataLook up a doctor →

Nissreen Elfadawy, MD

Nephrology · Chardon, OHNPI 1801226279

Payments from drug & device makers

$327,120in general payments, 2019–2025

Across 507 payments — averaging $645.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$180K
  • Otsuka America Pharmaceutical, Inc.$58K
  • AstraZeneca$49K
  • Sobi, Inc$27K
  • Novartis$9K
  • Fresenius USA Marketing, Inc.$1K
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$28,6719%
  • Speaking & faculty fees$240,41473%
  • Travel & lodging$44,38414%
  • Food & beverage$13,4154%
  • Education$2350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$327,120 in reported general payments places this provider in the 95th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$123,507
Medicare patients
396
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol333$300,235
KerendiaFinerenone47$52,201
JardianceEmpagliflozin49$37,298
LokelmaSodium Zirconium Cyclosilicate40$33,392
Febuxostat105$15,082
InvokanaCanagliflozin11$14,996
Potassium Citrate ErPotassium Citrate18$2,637
Potassium Chloride108$2,260
Chlorthalidone125$1,935
Losartan Potassium341$1,756
Allopurinol261$1,234
Amlodipine Besylate194$1,095
Calcitriol46$1,042
Cinacalcet Hcl17$889
Sevelamer Carbonate16$757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$48,588$333,627373 claims
BayerKerendia$92$52,20147 claims
Boehringer IngelheimJardiance$52$37,29849 claims
ANI Pharmaceuticals, Inc.Valsartan$28$33346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 nephrology providers in Ohio.

Other nephrology in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →